Sunshine Biopharma Inc.

Company Overview

Business Model: Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines across various therapeutic areas, including oncology and antivirals. The Company operates through two wholly-owned subsidiaries: Nora Pharma Inc., which commercializes 70 generic prescription drugs in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) supplements. Additionally, Sunshine Biopharma Inc. is advancing a proprietary drug development program focused on K1.1 mRNA, an LNP encapsulated mRNA therapy for liver cancer, and SBFM-PL4, a protease inhibitor for SARS Coronavirus infections. Commercial operations primarily involve securing rights to pharmaceutical products for sale in Canada through in-licensing, cross-licensing, and distribution agreements.

Market Position: Nora Pharma Inc. currently has 70 generic prescription drugs on the Canadian market and an additional 64 drugs in its pipeline, with 13 anticipated for launch in 2025. The Company aims to strengthen its presence in the Canadian generic drugs market, valued at approximately $9.7 billion USD in 2023 and projected to reach $19.2 billion USD by 2032. Nora Pharma Inc. is noted for demonstrating one of the fastest year-over-year sales growth rates among its peers in this market. In proprietary drug development, K1.1 mRNA has shown efficacy in destroying various cancer cells in vitro and reducing liver cancer tumors in xenograft mice. SBFM-PL4 has demonstrated sub micromolar activity against PLpro, antiviral activity in SARS-CoV-2 infected cells and variants, favorable pharmacokinetics, and significant virus load reduction in infected mouse models. The Company's Essential•9™ OTC product is positioned as the only Essential Amino Acid product comprising all 9 essential amino acids in capsule form.

Recent Strategic Developments:

• Commercial Expansion: Nora Pharma Inc. expanded its sales efforts into the Canadian provinces of Ontario, Alberta, and British Columbia, in addition to Quebec, and increased its product offerings by 5 generic drugs during 2024.
• Pipeline Advancement: The Company has 64 additional generic drugs in its pipeline, with 13 expected to launch in 2025.
• Regulatory Tailwinds: The Canadian federal government's Pharmacare Act, which became law on February 10, 2024, is expected to further strengthen the Canadian generic drugs market.
• K1.1 mRNA Development: Initiated research in June 2021, filed a provisional patent application in the United States on April 20, 2022, and entered an agreement with a commercial partner in November 2022 for LNP formulation. Initial animal testing results showed tumor size reduction in xenograft mice.
• SBFM-PL4 Development: Filed a patent application in the United States on May 22, 2020, and a PCT application on April 30, 2021. Entered a research agreement with the University of Arizona in February 2022, subsequently exercising an option and entering an exclusive worldwide license agreement on February 24, 2023. Research results were published in the Journal of Medicinal Chemistry in August 2024.
• Financing Activities: Completed an underwritten public offering on February 15, 2024, generating net proceeds of $8,522,411.
• Warrant Redemption: Redeemed all April Warrants and May Investor Warrants for an aggregate purchase price of $3,139,651 on February 11, 2024.
• Post-Period Product Additions: Since December 31, 2024, the Company has added 5 new generic prescription drugs, bringing the total to 70.

Geographic Footprint: Sunshine Biopharma Inc. maintains its principal place of business in Fort Lauderdale, FL, U.S. Its commercial operations for generic drugs are primarily in Canada, with sales in Quebec, Ontario, Alberta, and British Columbia. OTC products are sold in the U.S. and Canada via Amazon.com and Amazon.ca. Proprietary drug development activities are conducted in the U.S. (University of Arizona for Anti-Coronavirus compounds) and Hong Kong, China (WuXi App Tech for K1.1 mRNA). Generic drugs are manufactured by international partners, while OTC products are manufactured under contract in Montreal, Canada. Nora Pharma Inc. operates a 23,500 square foot facility in Varennes, Quebec, Canada, which includes warehouse and office space.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 30.60% (2024)
• Operating Margin: -16.66% (2024)
• Net Margin: -14.72% (2024)

Investment in Growth:

• R&D Expenditure: $933,902 (2.68% of revenue)
• Capital Expenditures: $1,979,313 (comprising $322,258 for intangible assets and $1,657,055 for equipment)
• Strategic Investments: Acquisition of intangible assets and equipment for Nora Pharma Inc. operations.

Business Segment Analysis

Commercial Operations (Generic Drugs & OTC Supplements)

Financial Performance:

• Revenue: $34,874,283 (+44.75% YoY)
• Gross Profit: $10,669,794 (+27.95% YoY)
• Cost of Sales: $24,204,489 (69.4% of revenue), an increase from 65.4% in 2023, primarily due to higher professional allowances incurred on sales outside Quebec where allowances are capped by government regulations.
• Key Growth Drivers: Expansion of Nora Pharma Inc.'s sales efforts into new Canadian provinces (Ontario, Alberta, British Columbia) and an increase of 5 new generic products offered in 2024. The Canadian Pharmacare Act, which became law in February 2024, is expected to further strengthen the generic drugs market. Product Portfolio:
• Major product lines and services within segment: 70 generic prescription drugs on the market in Canada, addressing therapeutic areas such as oncology, cardiovascular, central nervous system, diabetes, urology, and anti-infectives. Key examples include Abiraterone (Oncology), Apixaban (Cardiovascular), Dasatinib (Oncology), Dapagliflozin (Diabetes), Rivaroxaban (Cardiovascular), Rosuvastatin (Cardiovascular), Sildenafil (Urology), and Tadalafil (Urology).
• New product launches or major updates: 5 new generic prescription drugs added in 2024, with 13 more anticipated for launch in 2025 from a pipeline of 64 additional drugs.
• OTC products include Essential•9™, Calcium-Vitamin D, L-Citrulline, and Taurine. Market Dynamics:
• Competitive positioning within segment: Nora Pharma Inc. is a relatively new entrant in the Canadian generic pharmaceuticals market, which was valued at approximately $9.7 billion USD in 2023, but has demonstrated one of the fastest year-over-year sales growth rates among its peers.
• Key customer types and market trends: Sales are conducted through retail pharmacies, pharmacy channels, distributors, and wholesalers in Canada. Generic drug pricing is influenced by the pan-Canadian Pharmaceutical Alliance (pCPA) and governmental policies. OTC products are sold directly to consumers via Amazon.com and Amazon.ca.

Research and Development (Proprietary Drugs)

Financial Performance:

• R&D Expenditure: $933,902 in 2024, a decrease from $1,855,830 in 2023. Product Portfolio:
• K1.1 mRNA: An LNP encapsulated mRNA targeted for liver cancer.
  • Development Stage: Animal Testing.
  • Key Developments: Demonstrated in vitro destruction of multidrug resistant breast cancer, ovarian adenocarcinoma, and pancreatic cancer cells with minimal cytotoxicity to normal human cells. Initial animal testing showed effectiveness in reducing liver cancer tumors in xenograft mice.
• SBFM-PL4: A small molecule protease inhibitor for the treatment of SARS Coronavirus infections (including SARS-CoV-2, SARS-CoV, and MERS-CoV).
  • Development Stage: Animal Testing.
  • Key Developments: Active at sub micromolar concentrations against PLpro, exhibited antiviral activity in SARS-CoV-2 infected cells and various variants of concern. Demonstrated favorable pharmacokinetics in rodents with preferred drug accumulation in the lungs. Orally active in a K18-human-ACE2 transgenic mouse model, significantly reducing virus load in the lungs in a dose-dependent manner without gross toxicities. Research results published in the Journal of Medicinal Chemistry in August 2024.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $3,139,651 in 2024 for the redemption of April Warrants and May Investor Warrants. In 2023, $541,143 was used for stock repurchases (2,228 shares at an average price of $2,274.20 per share and 34 shares at an average price of $1,009.20 per share).
• Dividend Payments: $0.0 billion. The Company has not paid dividends to date and does not anticipate paying any in the foreseeable future, intending to retain earnings for future expansion and business plan implementation.
• Dividend Yield: N/A
• Future Capital Return Commitments: A stock repurchase program of up to $2 million was announced on January 19, 2023.

Balance Sheet Position:

• Cash and Equivalents: $9,686,529 (as of December 31, 2024)
• Total Debt: $952,480 (comprising current lease liabilities of $207,756 and long-term lease liabilities of $744,724). The Company had no notes payable as of December 31, 2024.
• Net Cash Position: $8,734,049
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Lease liabilities mature as follows: $207,756 in 2025, $197,595 in 2026, $195,760 in 2027, $177,669 in 2028, $168,462 in 2029, and $13,627 thereafter.

Cash Flow Generation:

• Operating Cash Flow: ($12,531,180) (used in operations)
• Free Cash Flow: ($14,510,493) (estimated as operating cash flow less capital expenditures)
• Cash Conversion Metrics: Cash used in operations increased in 2024 due to the expansion of Nora Pharma Inc.'s operations and an increase in inventory from $5,734,755 in 2023 to $11,278,105 in 2024.

Operational Excellence

Production & Service Model:

• Generic Drugs: Manufactured by various international partners (licensors or distribution partners) under long-term contracts. Sunshine Biopharma Inc. purchases finished goods from these partners. All production adheres to Good Manufacturing Practice (GMP) guidelines.
• Proprietary Drug Candidates: Research quantities are manufactured at the University of Arizona (Anti-Coronavirus compounds) and WuXi App Tech in Hong Kong, China (K1.1 mRNA).
• OTC Products: Manufactured under contract by INOV Pharma Inc. in Montreal, Canada.
• Operational Philosophy: Focus on securing regulatory approvals (DINs, NPNs) from Health Canada and ensuring compliance with GMP guidelines for all products.

Supply Chain Architecture:

• Key Suppliers & Partners:
  • Generic Drug Manufacturers: Various international partners.
  • Proprietary Drug Manufacturers (Research): University of Arizona (Anti-Coronavirus compounds), WuXi App Tech (K1.1 mRNA).
  • OTC Product Manufacturer: INOV Pharma Inc. (Montreal, Canada).
  • Raw Material Suppliers: Outside manufacturers source raw materials from a limited number of suppliers.
• Supply Chain Risks: The Company is exposed to supply chain discontinuities due to macroeconomic issues, regulatory actions, trade restrictions, labor disturbances, and approval delays, particularly as nearly all generic drugs are manufactured outside Canada and the United States.

Facility Network:

• Principal Office: 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301 (month-to-month lease, sufficient for the next year).
• Nora Pharma Inc. Facility: 1565 Boulevard Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7. This 23,500 square foot facility (18,500 sq ft warehouse, 5,000 sq ft office) houses administrative, marketing, quality control, regulatory affairs, and a Health Canada licensed warehouse. The lease expires in January 2030 with a 5-year extension option.
• Manufacturing: Distributed across international partners, the University of Arizona, WuXi App Tech, and INOV Pharma Inc.

Operational Metrics:

• The Nora Pharma Inc. facility is estimated to be adequate for annual sales of approximately $50 million to $75 million, beyond which additional space will be required.

Market Access & Customer Relationships

Go-to-Market Strategy:

• Direct Sales: Nora Pharma Inc. employs sales representatives to conduct all generic drug sales directly to pharmacies in Canada.
• Channel Partners: The marketing team provides human resources, commercial and technical assistance, and training/educational support to pharmacy owners.
• Digital Platforms: OTC products are sold through online channels, specifically Amazon.com in the U.S. and Amazon.ca in Canada.

Customer Portfolio:

• Enterprise Customers: The Company primarily sells its generic pharmaceutical products to registered pharmacies, pharmacy channels, distributors, and wholesalers in several Canadian provinces.
• Strategic Partnerships: Nora Pharma Inc. secures in-licenses, cross-licenses, and distribution agreements with international pharmaceutical partners.
• Customer Concentration: A significant portion of Nora Pharma Inc.'s revenues is derived from a relatively small number of key customers, posing a concentration risk.
• Government Payors: Provincial governments in Canada, and now the Canadian federal government through the Pharmacare Act, are key payors in the generic drug reimbursement programs, influencing pricing and market access.

Geographic Revenue Distribution:

• Canada: Primary market for generic drug sales, with efforts focused on Quebec, Ontario, Alberta, and British Columbia.
• U.S. & Canada: Markets for OTC product sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Canadian generic pharmaceuticals market was valued at approximately $9.7 billion USD in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.9% to $19.2 billion USD by 2032. This market is characterized by over 35 active generic players, with the top 3 holding approximately 50% of the total market share. Generic drug prices are subject to decline due to increased competition and accelerated approvals. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Generic Pharmaceuticals: Over 35 active generic players in the Canadian market.
• Anti-Coronavirus Treatments: Pfizer, Merck, Gilead, Eli Lilly, and Regeneron, which have developed effective vaccines, antiviral pills (Paxlovid, Molnupiravir), and antibody treatments (Remdesivir).
• Anticancer Drug Development: Large pharmaceutical companies such as Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb, and Novartis, as well as numerous smaller biotechnology companies.
• OTC Products: A crowded and highly competitive sector. Emerging Competitive Threats: New market entrants, disruptive technologies, and alternative solutions in both generic and proprietary drug development. Brand pharmaceutical companies may also introduce authorized generics or employ tactics to delay generic market entry. Competitive Response Strategy: For generic drugs, the Company's strategy involves expanding its product portfolio and sales efforts within Canada. For Anti-Coronavirus, it focuses on developing a PLpro inhibitor that targets a different viral mechanism, potentially offering an alternative for patients unable to use existing treatments. For anticancer, it is developing novel mRNA-based therapies. For OTC, it differentiates Essential•9™ by its unique composition of all 9 essential amino acids in capsule form.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Generic Drug Volatility: The generic pharmaceutical business faces increased volatility in volumes due to global supply chain issues and macroeconomic pressures (e.g., rising inflation, geopolitical conflicts).
• Pricing Pressures: Sales of generic products are susceptible to fluctuations in customer buying patterns and government-led pricing pressures in Canada, which can erode profitability.
• Market Acceptance: Even if proprietary drug candidates receive regulatory approval, there is no assurance of market acceptance by physicians, patients, and payors, which depends on factors like safety, efficacy, convenience, and cost-effectiveness. Technology Disruption:
• Competitive Innovation: Competitors with greater resources may develop more effective or less costly products, potentially rendering Sunshine Biopharma Inc.'s technology or product candidates obsolete. Customer Concentration:
• Revenue Dependency: A significant portion of Nora Pharma Inc.'s revenues is derived from a relatively small number of key customers, creating a dependency risk.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Nearly all generic drugs are manufactured outside Canada and the U.S., making the Company vulnerable to supply discontinuities caused by macroeconomic issues, regulatory actions, trade restrictions, labor disturbances, and approval delays. Raw materials are sourced from a limited number of suppliers.
• Capacity Constraints: Third-party manufacturers may not be able to scale up production of proprietary drug candidates in a timely or economic manner, potentially delaying commercialization. Nora Pharma Inc.'s current facility capacity is limited to $50-$75 million in annual sales.
• Manufacturing Quality: Reliance on third-party manufacturers exposes the Company to risks of manufacturing errors, which could lead to patient injury, product recalls, or delays. Growth Management:
• Resource Strain: Rapid growth could impose a significant burden on administrative and operational resources, requiring substantial expansion of personnel and capabilities. Product Liability:
• Inherent Risks: The testing, manufacturing, and marketing of pharmaceutical products inherently carry product liability risks, which will increase if proprietary candidates are commercialized. Current insurance may not provide adequate protection. Hazardous Materials:
• Environmental Compliance: Research and development activities involve hazardous materials, subjecting the Company to environmental laws and regulations, with potential liability for damages or fines from non-compliance.

Financial & Regulatory Risks

Market & Financial Risks:

• Demand Volatility: A significant or prolonged economic downturn could adversely affect consumer disposable income and demand for some products.
• Foreign Exchange: Financial statements of Canadian subsidiaries are translated into USD, exposing the Company to foreign exchange rate fluctuations.
• Credit & Liquidity: The Company has incurred significant net losses ($5.1 million in 2024, $4.5 million in 2023) and has an accumulated deficit of $69.0 million. It will require substantial additional funding for future operations, R&D, and potential clinical trials, with no committed sources of capital. Regulatory & Compliance Risks:
• Extensive Regulation: All business operations are subject to extensive and frequently changing federal, state, provincial, and local laws and regulations, including those from the FDA and Health Canada.
• Proprietary Drug Approval: Proprietary drug candidates require extensive and costly development, preclinical testing, and clinical trials to obtain regulatory approval, a process that is lengthy and highly uncertain. No filings have been made with the FDA for proprietary drugs to date.
• Generic Drug Pricing: Generic drug prices in Canada are highly dependent on governmental policies and negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA). Nasdaq Listing:
• Delisting Risk: The Company has experienced significant volatility in its common stock price and has faced delisting notifications from Nasdaq due to bid price non-compliance and concerns regarding the "alternative cashless exercise" provision of Series A Warrants. While bid price compliance was regained, the Company is subject to a one-year Mandatory Panel Monitor, with potential for delisting if non-compliance recurs.

Geopolitical & External Risks

Geopolitical Exposure:

• Global Supply Chain: Geopolitical conflicts and trade tensions can destabilize global supply chains, particularly impacting the Company's generic drug business which relies on international manufacturers. Adverse Publicity:
• Reputational Damage: Negative public perception or adverse publicity regarding the Company, its products, or the industry could materially affect sales and revenues. Catastrophic Events:
• Operational Disruption: Manufacturing and third-party fulfillment activities are vulnerable to power failures, border shutdowns, natural disasters, pandemics, and other catastrophic events.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Oncology (Liver Cancer): Investment in K1.1 mRNA molecules, utilizing lipid nanoparticle (LNP) technology for targeted delivery. This area is strategically important for developing novel anti-cancer agents.
• Antiviral (SARS Coronavirus): Focus on small molecule inhibitors targeting the Coronavirus main protease (Mpro) and papain-like protease (PLpro), which are essential for viral replication and immune system suppression. Innovation Pipeline:
• K1.1 mRNA: Currently in animal testing, with initial results showing tumor reduction in xenograft mice. Further dose-response studies are underway.
• SBFM-PL4: Also in animal testing, demonstrating potent antiviral activity and favorable pharmacokinetics. Research results have been published in a peer-reviewed journal.
• Generic Drug Pipeline: 64 additional generic drugs are in the pipeline, with 13 slated for launch in 2025, indicating a continuous effort to expand the commercial product portfolio.

Intellectual Property Portfolio:

• Patent Strategy:
  • Provisional patent application filed in the United States on April 20, 2022, covering K1.1 mRNA molecules (composition and utility).
  • Patent application filed in the United States on May 22, 2020, and a PCT application on April 30, 2021, covering small molecules for inhibition of Coronavirus Mpro and PLpro.
• Licensing Programs:
  • Nora Pharma Inc. owns 200 Drug Identification Numbers (DINs) issued by Health Canada for generic prescription drugs, obtained through in-licenses or cross-licenses from international manufacturers.
  • Exclusive worldwide license agreement with the University of Arizona (effective February 24, 2023) for three patents related to small molecules inhibiting Coronavirus PLpro.
• NPNs: Owns four Natural Product Numbers (NPNs) issued by Health Canada for OTC products: Essential•9™, Calcium-Vitamin D, L-Citrulline, and Taurine.

Technology Partnerships:

• Strategic Alliances: Agreement with a specialized commercial partner for formulating K1.1 mRNA molecules into specific lipid nanoparticles for animal testing.
• Research Collaborations: Research agreement with the University of Arizona for in vivo studies of PLpro inhibitors, leading to an exclusive worldwide license agreement.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company has employment agreements with its CEO, CFO, COO, and CCO, all with indefinite terms. These agreements include severance provisions in the event of termination without cause or for good reason, aiming to ensure leadership stability. Board Composition: The Board of Directors includes Dr. Steve N. Slilaty (Chairman), Dr. Abderrazzak Merzouki (Director), Dr. Rabi Kiderchah (Independent Director), Mr. David Natan (Independent Director and Audit Committee Financial Expert), and Dr. Andrew Keller (Independent Director). The Board has established an audit committee, a compensation committee, and a corporate governance and nominating committee, each composed of independent directors.

Human Capital Strategy

Workforce Composition:

• Total Employees: 52 employees as of the date of the report.
• Skill Mix: Proprietary drug development activities are primarily subcontracted to specialized service providers and consultants, indicating a lean internal R&D workforce supplemented by external expertise. Talent Management:
• Acquisition & Retention: The Company relies significantly on the services of Dr. Steve N. Slilaty for strategic, operational, and scientific management, with his loss posing a substantial negative impact risk.
• Employee Value Proposition: Employees in Quebec are subject to provincial labor laws providing guaranteed minimum entitlements, including wages, maternity leave, medical leave, and termination conditions. Diversity & Development:
• Culture & Engagement: Corporate operations in Quebec are conducted largely in French, in compliance with provincial language laws.

Environmental & Social Impact

Environmental Commitments: Climate Strategy:

• The Company's research and development activities involve the use of controlled and hazardous materials and chemicals. Supply Chain Sustainability:
• The Company is subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials and waste products. Social Impact Initiatives:
• No specific social impact initiatives beyond general compliance with labor and language laws were explicitly disclosed in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: The Company's business is sensitive to economic downturns, which can adversely affect consumer disposable income and potentially lower demand for some products.
• Industry Cycles: The generic pharmaceutical market is subject to pricing pressures and competition, which can impact sales and profitability over time. Planning & Forecasting:
• Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Regulation: The U.S. Food and Drug Administration (FDA) regulates prescription drugs and nonprescription OTC supplements, while the Federal Trade Commission (FTC) regulates marketing and advertising claims. Manufacturing processes and facilities must meet Good Manufacturing Practices (GMP) requirements.
• Canadian Regulation: Health Canada is the primary regulatory body, issuing Drug Identification Numbers (DINs) for prescription drugs and Natural Product Numbers (NPNs) for natural products. Generic drug submissions (Abbreviated New Drug Submissions - ANDS) are reviewed by Health Canada's Health Products and Food Branch (HPFB).
• Proprietary Drug Development: Subject to a multi-phase approval process in the U.S., including Investigational New Drug (IND) applications, Phase I, II, and III clinical trials, and New Drug Applications (NDAs). Emergency Use Authorization (EUA) or compassionate-use approval may be possible for terminally ill patients. No filings have been made with the FDA for proprietary drugs to date.
• Generic Drug Pricing: The pan-Canadian Pharmaceutical Alliance (pCPA) determines generic drug pricing in Canada, and the recent Pharmacare Act has made the Canadian federal government an additional payor in the reimbursement program. Trade & Export Controls:
• Export Restrictions: Products sold by Sunshine Biopharma Inc. are labeled and approved for sale in Canada only and are not intended for export outside of Canada. Legal Proceedings:
• The Company is not currently a party to any legal proceedings, nor is it aware of any threats of such actions against it.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 4.40% (2024).
• Geographic Tax Planning: The Company's Canadian subsidiaries have the Canadian dollar as their functional currency, with financial statements translated into U.S. dollars, which can result in translation adjustments.
• Tax Reform Impact: The Company's 2021 through 2023 tax years remain open for examination by tax authorities.
• No uncertain tax positions as of December 31, 2024.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: The Company maintains product liability insurance for its generic drugs and OTC products. It plans to obtain product liability insurance in connection with future clinical trials of its pharmaceutical product candidates.
• Risk Transfer Mechanisms: The Company does not currently have a pollution and remediation insurance policy, despite its R&D activities involving hazardous materials.